Mymetics

Mymetics Equity

The The Equity of Mymetics (MYMX) as of Oct 16, 2026 is -64.90 M EUR. In the previous year, The Equity was -60.09 M EUR — a change of 8.01% (lower).

Equity

-64.90 MEUR

YoY

8.01%

Last updated:

In 2022, Mymetics's equity was -64.90 M EUR, a 8.01% increase from the -60.09 M EUR equity in the previous year.

The Mymetics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
-32.89 M EUR
Jan 1, 2016
-38.78 M EUR
Jan 1, 2017
-42.88 M EUR
Jan 1, 2018
-47.03 M EUR
Jan 1, 2019
-51.20 M EUR
Jan 1, 2020
-55.35 M EUR
Jan 1, 2021
-60.09 M EUR
Jan 1, 2022
-64.90 M EUR
The Mymetics Equity history
YEAREquityYoY
-64.90 MEUR+8.01%
-60.09 MEUR+8.55%
-55.35 MEUR+8.11%
-51.20 MEUR+8.87%
-47.03 MEUR+9.67%
-42.88 MEUR+10.57%
-38.78 MEUR+17.90%
-32.89 MEUR+9.32%
-30.09 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mymetics Stock analysis

What does Mymetics do? Mymetics Corp, listed under the ticker MYMX with ISIN US62856A3005, is a biotechnology company based in Epalinges, Switzerland. The company operates within the Health Care sector, specifically in the Biotechnology industry. Mymetics Corp has an employee count of 8 and went public on February 10, 1995. The company's website is https://www.mymetics.com/. Mymetics Corp focuses on the research and development of virosome-based vaccines for infectious diseases. Virosomes are lipid-based carriers that incorporate functional fusion viral proteins and natural membrane proteins, combined with rationally designed antigens. The company has multiple vaccine candidates in its pipeline, including those targeting HIV-1/AIDS, influenza, malaria, herpes simplex virus (HSV), and respiratory syncytial virus (RSV). The HIV-1 vaccine candidate utilizes virosomes linked to conserved antigens derived from HIV-1 glycoprotein 41 (gp41) proteins of clade B. The RSV vaccine candidate is composed of reconstituted RSV membrane containing native viral proteins. Similarly, the HSV vaccine candidate consists of reconstituted membranes from HSV-1 or HSV-2, while the intranasal influenza vaccine includes reconstituted influenza virus membranes. Mymetics Corp's technology aims to develop prophylactic vaccines through these virosome-based approaches. The company's headquarters are located in Epalinges, Vaud, Switzerland. The firm's current focus is on advancing its pipeline of vaccine candidates for various infectious diseases through innovative virosome technology. Mymetics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Mymetics's Equity

Mymetics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mymetics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mymetics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mymetics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mymetics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mymetics stock

The Equity of Mymetics is -64.90 M EUR in 2022.

The Equity of Mymetics changed from -60.09 M EUR to -64.90 M EUR, representing a 8.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Mymetics since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Mymetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Mymetics

All Key Metrics — Mymetics